ライフサイエンスコーパス: veno-occlusive disease

1 17 patients (3%) had hepatic veno-occlusive disease.

2 is crucial for the development of pulmonary veno-occlusive disease.

3 transaminase and bilirubin without signs of veno-occlusive disease.

4 dysfunction, and a high frequency of hepatic veno-occlusive disease.

5 eveloped severe hepatotoxicity suggestive of veno-occlusive disease.

6 Two patients had reversible hepatic veno-occlusive disease.

7 used as therapy for Budd-Chiari syndrome and veno-occlusive disease.

8 or of 100-day mortality was the diagnosis of veno-occlusive disease.

9 acteristic that predicted the development of veno-occlusive disease.

10 ty, any infection, organ failure, or hepatic veno-occlusive disease (1-year cumulative incidence, 71%

11 d $20,500, respectively), whereas infection, veno-occlusive disease, acute graft-versus-host disease,

12 nary capillary hemangiomatosis and pulmonary veno-occlusive disease, an autosomal recessively inherit

13 Rates of veno-occlusive disease and interstitial pneumonitis were

14 tioned well initially, the patient developed veno-occlusive disease and required repeat transplantati

15 irected deletion of Aplnr manifest pulmonary veno-occlusive disease and right heart failure, detectab

16 elopment of sinusoidal obstruction syndrome (veno-occlusive disease) and by total serum bilirubin lev

17 erapy; (2) posttransplant fever; (3) hepatic veno-occlusive disease; and (4) use of posttransplant gr

18 ction (presenting as the syndrome of hepatic veno-occlusive disease) are all associated with signific

19 sease, organ failure, infections, or hepatic veno-occlusive disease between groups.

20 and 3 months of age as a result of pulmonary veno-occlusive disease, capillary hemorrhage, and pancyt

21 ary hypertension and differentiate pulmonary veno-occlusive disease from pulmonary arterial hypertens

22 sed as a common mechanism leading to hepatic veno-occlusive disease (HVOD).

23 was also a trend toward an increased risk of veno-occlusive disease in patients with high ferritin.

24 nusoidal obstruction syndrome (also known as veno-occlusive disease) in patients during study treatme

25 Pulmonary veno-occlusive disease is caused by excessive cell proli

26 Veno-occlusive disease occurred twice with cyclophospham

27 No additional cases of veno-occlusive disease occurred.

28 Severe veno-occlusive disease of the liver occurred in 9 (21%)

29 Additionally, 95 patients developed veno-occlusive disease of the liver.

30 ificant acute graft-versus-host disease, and veno-occlusive disease of the liver.

31 the initiation of pulmonary vasodilators in veno-occlusive disease often leads to increased mortalit

32 otaline administration led to severe hepatic veno-occlusive disease on day 6.

33 lantation-related mortality; acute toxicity (veno-occlusive disease or acute graft versus-host diseas

34 8-5.5), GVHD (OR, 2.4; 95% CI, 1.8-3.3), and veno-occlusive disease (OR, 2.2; 95% CI, 1.4-3.6).

35 Low L-Ficolin was associated with hepatic veno-occlusive disease (P = .0053, AUC = 0.80).

36 ients with a clinical diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatos

37 4 gene (EIF2AK4) are described in pulmonary veno-occlusive disease/pulmonary capillary hemangiomatos

38 opathic and heritable PAH and with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatos

39 athic or heritable PAH and 16 with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatos

40 Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonar

41 Pulmonary veno-occlusive disease (PVOD) is an uncommon form of pul

42 Pulmonary veno-occlusive disease (PVOD) is an uncommon form of pul

43 s (n=12) and patients with primary pulmonary veno-occlusive disease (PVOD; n=17).

44 en successfully used to treat severe hepatic veno-occlusive disease (sVOD) with multiorgan failure (M

45 Treosulfan causes less veno-occlusive disease than busulfan and does not requir

46 vely evaluated for the clinical diagnosis of veno-occlusive disease, the occurrence of acute graft-ve

47 ary ERG and APLNR in patients with pulmonary veno-occlusive disease undergoing lung transplantation w

48 n and melphalan group had Bearman grades 1-3 veno-occlusive disease versus 21 (9%) of 239 in the carb

49 Rates of veno-occlusive disease (VOD) and thrombotic microangiopa

50 bstruction syndrome (SOS), previously called veno-occlusive disease (VOD) can be a difficult problem

51 We noted an excess of veno-occlusive disease (VOD) in a clinical trial, and re

52 Hepatic veno-occlusive disease (VOD) is a common complication of

53 Hepatic veno-occlusive disease (VOD) is one of the most serious

54 Hepatic veno-occlusive disease (VOD) is the most common of the r

55 Veno-occlusive disease (VOD) is the most common regimen-

56 Hepatic veno-occlusive disease (VOD) is the most serious regimen

57 Veno-occlusive disease (VOD) is the third leading cause

58 One patient treated at 9 mg/m2 developed veno-occlusive disease (VOD) of the liver and defined th

59 The incidence of hepatic veno-occlusive disease (VOD) was 5% for IV-BU and 1% wit

60 Hepatic veno-occlusive disease (VOD), also called sinusoidal obs

61 ibrotide for the treatment of severe hepatic veno-occlusive disease (VOD), showing a 23% improvement

62 mg/m(2) per day after recognition of hepatic veno-occlusive disease (VOD).

63 had dose limiting toxicity (DLT), including veno-occlusive disease (VOD).

64 The incidence of veno-occlusive disease was 40% (13 of 32 patients) in pl

65 l recessive primary immunodeficiency disease veno-occlusive disease with immunodeficiency syndrome (V